Short answer: At an outpatient stem cell treatment visit, you can expect check-in, a health and consent review, identity checks, administration of the planned cell preparation, observation, and discharge instructions. The cells may be given through an IV or by a local injection, depending on the treatment. Your clinic should confirm the route, visit length, and discharge criteria in advance. Treatment may be postponed if a safety check raises a concern.
This guide covers outpatient cell-treatment visits, with regulatory context for Japan. It does not describe blood-forming stem cell transplantation for blood cancers or other specialist inpatient treatments. It is general information, not personal medical advice. A private-clinic intervention is not necessarily an approved treatment, and an uneventful visit does not establish that it will help your condition.
Before treatment day
Ask for written instructions about food, drink, medicines, transport, and any tests needed before arrival. Fasting depends on the procedure and whether sedation or anaesthesia is planned; do not assume an IV visit means you can eat normally. Tell the team about allergies, blood thinners, drugs that suppress your immune system, and any new illness. Do not stop a prescription without instructions from the clinician responsible for it.
Confirm whether the appointment includes cell collection or only administration of cells prepared earlier. Collection adds a separate procedure and may change the preparation and recovery plan. If sedation is planned, ask about an escort and driving restrictions.
Pack your ID, medicine and allergy lists, requested test results, and consent paperwork in one folder. Wear clothes that allow access to the planned IV or injection site. If you travel for treatment, keep your accommodation address and emergency contact with the same papers.
Checking in
Reception confirms your appointment and personal details. The clinical team reviews changes since your assessment, such as fever, infection symptoms, new medicines, or an allergy. Staff may measure your temperature, blood pressure, pulse, and oxygen level, and order further tests if needed. Ask what would cause the appointment to be delayed.
For treatment provided under Japan’s regenerative medicine safety framework, ask which filed provision plan applies and which medical institution is responsible. Filing is a regulatory requirement under that framework, not marketing approval of a product or proof of benefit for your condition. The ministry’s procedures include plan submission and reporting duties. Plan
For a practical waiting-room plan, keep your medicine list within reach and write down questions before you are called. If the schedule changes, ask which step is pending rather than guessing what the delay means.
Consent and identity
Before administration, confirm the cell source, preparation name, route, purpose, known risks, uncertainties, alternatives, and follow-up plan. Ask whether the intervention is an approved product used for its approved indication, a clinical trial, or a private-clinic service. These are different categories. You can ask questions or decline before proceeding.
If the source, route, dose, or price differs from what you agreed, pause and request an explanation in writing. Ask staff to explain how they match the preparation to you and document the batch or other traceability details. You can state your full name and date of birth during the identity check.
Your own cells are called autologous cells; cells from another person are allogeneic. For either source, ask how the preparation is identified and traced. Do not assume that using your own cells removes the risks of collection, processing, or administration.
How the cells are given
Intravenous infusion
For an IV infusion, staff place or use a line into a vein and administer the preparation according to the protocol. Ask about the planned infusion time, any medicines given beforehand, and how to call for help. Tell staff promptly about pain at the line, itching, chills, dizziness, chest discomfort, or breathing changes. Do not adjust the drip yourself.
Local injection
For a local injection, the clinician confirms the site and cleans the skin. Numbing medicine or imaging guidance may be used, depending on the procedure. What you feel and whether you remain fully awake depend on the site and anaesthetic plan. Ask what discomfort is expected and what would require assessment, rather than assuming pain or swelling must settle within a fixed number of days.
Before either procedure, ask who will respond to a reaction and what emergency support is available. There is no single risk rate that applies to all cell preparations and routes. In its US consumer warning, FDA describes reports involving unapproved regenerative products, including infections, unwanted immune or inflammatory responses, and other serious harm; these reports do not establish a rate for your proposed treatment in Japan. Important patient and consumer information about regenerative medicine therapies
Observation before discharge
After administration, staff observe you according to the treatment protocol and your condition. Ask how long observation is planned, what they will check, and what must be stable before you leave. Symptoms may mean further assessment or a longer stay. There is no universal observation time for every cell treatment.
Report new symptoms while you are still with the team. Do not dismiss fever, chills, rash, or worsening injection-site pain as a sign that the cells are working. Ask for help before standing or walking if you feel faint.
Paperwork before you leave
Request a treatment summary with the preparation name, cell source, route, date, responsible clinician, and available batch or traceability details. Also get written aftercare, the next review date, and contact instructions for both office hours and nights or weekends.
A useful discharge check is to ask: “If I develop a fever tonight, who do I call, and when should I go straight to emergency care?” Save the number in your phone and keep a copy of the summary where you can find it. If you use another language, request instructions you can understand and confirm any interpreter arrangements.
The first 72 hours
Use your own written aftercare plan. The first three days are a useful planning window, not a point after which all risks end. Before leaving, confirm:
How to care for the IV or injection site, including dressing changes, bathing, and signs of infection.
When to restart work, exercise, driving, or weight-bearing after a joint procedure.
Which regular medicines to continue and whether any changes were prescribed.
Which symptoms to record, which need a same-day call, and which need emergency help.
When you can travel and how follow-up will work if you return home.
Do not book a long flight on the assumption that discharge means you are fit to fly. Discuss the procedure, any sedation, your medical history, and your risk during prolonged travel with the treating doctor. Carry your treatment summary and know where to seek care at your destination.
When to seek care
Seek emergency help immediately for breathing difficulty, chest pain, fainting, swelling of the face or tongue, or sudden severe symptoms. Do not wait for a clinic email or callback. Breathing difficulty and sudden throat or tongue swelling can be signs of a life-threatening allergic reaction. Anaphylaxis New one-sided leg swelling needs urgent medical assessment; if it occurs with chest pain or breathlessness, seek emergency help.
Contact the clinical team promptly for fever, shaking chills, a new rash, spreading redness, discharge, or worsening pain at the treatment site. Follow any stricter instructions they gave you. If you feel very unwell, symptoms are worsening, or you cannot reach the team, seek urgent care rather than waiting.
Show the clinician your treatment summary and explain when, where, and by which route you received the cells. New problems after the initial recovery period still need assessment.
What the day cannot prove
An uneventful administration does not show whether an intervention works or exclude later harm. Japan’s regulatory counts also describe different things, not treatment success:
Japan regulatory snapshot
Dated figure and meaning
Filed treatment provision plans
6,743 as of 30 June 2026: Class I 8, Class II 2,463, and Class III 4,272. The ministry also listed 85 research plans. These are plan counts, not patient outcomes. 001590173.pdf
Review committees and processing facilities
The same 30 June 2026 snapshot listed 167 committees and 3,671 cell-processing facilities; these counts do not establish the benefit of an individual intervention. 001590173.pdf
Regenerative medical product approvals
PMDA’s 20 May 2026 presentation counted 26 granted approvals, including two withdrawn or expired approvals. This broad product category includes gene therapies as well as cell/tissue-based products; it is not a count of approved outpatient stem cell treatments. 000280868.pdf
Ask for evidence specific to your condition, the exact cell preparation, and the proposed route. A plan filing does not replace that evidence. If you improve later, other treatment, rehabilitation, or natural changes in symptoms may also contribute. Agree on what will be measured, when it will be reviewed, and what would justify stopping rather than booking further sessions automatically.
Common questions
How long will I be at the clinic?
Ask for separate estimates for preparation, administration, observation, and any collection procedure. One clinic’s timetable may not apply to your plan. Keep the rest of the day flexible until the team confirms your discharge and transport arrangements.
Does it hurt?
Needle placement and local injections can cause discomfort. The site, technique, and anaesthetic plan affect what you feel. Ask about pain relief in advance and report unexpected or worsening pain during the visit.
Can treatment be postponed that day?
Yes. A new illness, concerning test result, missing information, or a mismatch between the preparation and the agreed plan may require reassessment. Ask what needs to be resolved before rebooking.
Will I feel better immediately?
How you feel on the way home is not a reliable test of treatment benefit. Use the agreed follow-up measures, and do not interpret a reaction or discomfort as proof that treatment is effective.
What if I go home to another country?
Confirm travel clearance, follow-up dates, records access, and a contact route across time zones. Identify local care before you leave Japan. For emergency symptoms, use local emergency services rather than waiting for the overseas clinic.
Bottom line
For an outpatient visit, treatment day runs from safety checks and consent through administration, observation, and a written discharge plan. Before leaving, know what you received, what to do if symptoms develop, and when the next clinical review will happen. A smooth visit is not a guarantee of benefit.
Questions about visit arrangements?
Use the enquiry form for questions about appointment preparation and patient support. It is not an emergency contact.